Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was acquired at an average price of $15.34 per share, for a total transaction of $153,400.00. Following the completion of the purchase, the director now directly owns 106,062 shares in the company, valued at $1,626,991.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) traded up $0.41 on Monday, hitting $15.79. The stock had a trading volume of 8,381,866 shares, compared to its average volume of 12,850,000. Valeant Pharmaceuticals Intl Inc has a 1 year low of $8.31 and a 1 year high of $24.43. The company has a debt-to-equity ratio of 4.25, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market cap of $5,510.00, a PE ratio of 3.88, a P/E/G ratio of 0.52 and a beta of -0.28.

How to Become a New Pot Stock Millionaire

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The firm had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.18 billion. During the same period in the prior year, the business earned $1.26 EPS. The company’s revenue for the quarter was down 10.0% compared to the same quarter last year. research analysts expect that Valeant Pharmaceuticals Intl Inc will post 3.12 EPS for the current fiscal year.

A number of brokerages have weighed in on VRX. Zacks Investment Research lowered Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 13th. HC Wainwright upped their target price on Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. TD Securities upped their target price on Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Wells Fargo & Co restated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, January 4th. Finally, Goldman Sachs Group began coverage on Valeant Pharmaceuticals Intl in a research note on Wednesday, January 24th. They issued a “sell” rating and a $18.00 target price on the stock. Seven research analysts have rated the stock with a sell rating, ten have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $18.30.

Several institutional investors and hedge funds have recently bought and sold shares of VRX. Northern Trust Corp boosted its holdings in Valeant Pharmaceuticals Intl by 63.7% during the 2nd quarter. Northern Trust Corp now owns 326,013 shares of the specialty pharmaceutical company’s stock valued at $5,640,000 after acquiring an additional 126,851 shares during the period. Nationwide Fund Advisors boosted its holdings in Valeant Pharmaceuticals Intl by 25.0% during the 3rd quarter. Nationwide Fund Advisors now owns 65,480 shares of the specialty pharmaceutical company’s stock valued at $938,000 after acquiring an additional 13,080 shares during the period. Aperio Group LLC boosted its holdings in Valeant Pharmaceuticals Intl by 53.5% during the 3rd quarter. Aperio Group LLC now owns 187,803 shares of the specialty pharmaceutical company’s stock valued at $2,691,000 after acquiring an additional 65,424 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in Valeant Pharmaceuticals Intl during the 3rd quarter valued at about $490,000. Finally, Andra AP fonden boosted its holdings in Valeant Pharmaceuticals Intl by 35.0% during the 3rd quarter. Andra AP fonden now owns 98,800 shares of the specialty pharmaceutical company’s stock valued at $1,767,000 after acquiring an additional 25,600 shares during the period. Hedge funds and other institutional investors own 50.12% of the company’s stock.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-intl-inc-vrx-director-acquires-153400-00-in-stock/1926218.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Insider Buying and Selling by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.